The field of nanomedicines has expanded significantly in recent years in the breadth of
compounds under development as well as in the types of technology that are being applied …

The development and clinical application of inhibitors that target the epidermal growth factor
receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the …

Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth
factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as …

Objective To establish evidence-based recommendations for the molecular analysis of lung
cancers that are that are required to guide EGFR-and ALK-directed therapies, addressing …

Mutations in the epidermal growth factor receptor (EGFR) gene are commonly observed in
non-small-cell lung cancer (NSCLC), particularly in tumors of adenocarcinoma (ADC) …

Background The use of tyrosine kinase inhibitors to target the epidermal growth factor
receptor gene (EGFR) in patients with non–small-cell lung cancer is effective but limited by …

Purpose: Epithelial–mesenchymal transition (EMT) has been associated with metastatic
spread and EGF receptor (EGFR) inhibitor resistance. We developed and validated a robust …

Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …

Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic
kinase activity that transduces important growth factor signaling from the extracellular milieu …

The tumour-suppressor phosphatase with tensin homology (PTEN) is the most important
negative regulator of the cell-survival signalling pathway initiated by phosphatidylinositol 3 …